Literature DB >> 2002966

Radiolabelled monoclonal antibodies in oncology. II. Clinical applications in diagnosis.

M Granowska1, K E Britton.   

Abstract

The clinical applications of this approach to the management of patients with ovarian cancer and of patients with colorectal cancer are emphasized. The introduction of stable 99Tcm labelling of monoclonal antibodies means that radioimmunoscintigraphy is able to become routinely available in nuclear medicine departments.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2002966     DOI： 10.1097/00006231-199102000-00002

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN： 0143-3636            Impact factor:   1.690


  5 in total

Review 1.  Nuclear medicine.

Authors:  P J Ell
Journal:  Postgrad Med J       Date:  1992-02       Impact factor: 2.401

Review 2.  Does immunoscintigraphy serve clinical needs effectively? Is there a future for radioimmunotherapy?

Authors:  J F Chatal; P Peltier; M Bardiès; A Chétanneau; P Thedrez; A Faivre-Chauvet; J F Gestin
Journal:  Eur J Nucl Med       Date:  1992

3.  Superimposition of computed tomography and single photon emission tomography immunoscintigraphic images in the pelvis: validation in patients with colorectal or ovarian carcinoma recurrence.

Authors:  J C Liehn; A Loboguerrero; C Pérault; L Demange
Journal:  Eur J Nucl Med       Date:  1992

4.  Radioimmunoscintigraphy with technetium-99m-labelled monoclonal antibody, SM3, in gynaecological cancer.

Authors:  M Granowska; K E Britton; S J Mather; D G Lowe; D Ellison; J Bomanji; J Burchell; J Taylor-Papadimitriou; C R Hudson; J H Shepherd
Journal:  Eur J Nucl Med       Date:  1993-06

5.  Evaluation of a technique for the intraoperative detection of a radiolabelled monoclonal antibody against colorectal cancer.

Authors:  W A Waddington; B R Davidson; A Todd-Pokropek; P B Boulos; M D Short
Journal:  Eur J Nucl Med       Date:  1991
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.